These discrepancies in clinical response may be explained by individual PBRM1 mutations not being functionally equivalent; instead, different classes of PBRM1 mutations may have unique impacts on overall protein stability and activity in the context of cancer. The gene discussed is PBRM1; the disease is cancer.